A phase Ib study of a single priming dose of 177Lu-PSMA617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)

被引：0
|
作者：
Aggarwal, R. [1 ]
Trihy, L. [2 ]
Hernandez Romero, E. [2 ]
Sam, S. Luch [1 ]
Rastogi, M. [1 ]
De Kouchkovsky, I. [3 ]
Small, E. J. [4 ]
Feng, F. [5 ]
Kwon, D. [3 ]
Friedlander, T. [3 ]
Borno, H. T. [3 ]
Bose, R. [6 ]
Chou, J. [3 ]
Koshkin, V. S. [7 ]
Desai, A. [8 ]
Feng, S. [2 ]
Angelidakis, A. [2 ]
Johnson, M. S. [9 ]
Fong, L. [10 ]
Hope, T. [11 ]
机构：
[1] Univ Calif San Francisco, Med Dept, Parnassus Campus, San Francisco, CA USA
[2] UCSF Univ Calif San Francisco, Canc Ctr, San Francisco, CA USA
[3] UCSF Univ Calif San Francisco, Med, San Francisco, CA USA
[4] UCSF Helen Diller Family Comprehens Canc Ctr, Comprehens Canc Ctr, San Francisco, CA USA
[5] UCSF Univ Calif San Francisco, Radiat Oncol, Parnassus Campus, San Francisco, CA USA
[6] UCSF Univ Calif San Francisco, Anat, San Francisco, CA USA
[7] UCSF Helen Diller Family Comprehens Canc Ctr, Div Med Oncol, San Francisco, CA USA
[8] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[9] UCSF Med Ctr Mission Bay, Genitourinary Oncol Dept, San Francisco, CA USA
[10] UCSF Diabet Teaching Ctr, Med Dept, San Francisco, CA USA
[11] UCSF Univ Calif San Francisco, Radiol, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1379P
引用
收藏
页码：S1173 / S1173
页数：1
相关论文
共 50 条
  • [21] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [22] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [23] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [24] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [25] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
    Rohith, Gorrepati
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
  • [26] 177Lu-PSMA-617 Treatment of Metastatic Castration-Resistant Prostate Cancer: Efficacy and Survival
    Demirci, E.
    Akyel, R.
    Sahin, O.
    Ocak, M.
    Aygun, A.
    Pehlivanoglu, H.
    Karayel, E.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S203
  • [27] Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02) : 106 - 106
  • [28] Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer
    Tann, Mark
    Sims, Justin
    Auxier, Ashleigh
    Althouse, Sandra K.
    Salous, Tareq
    King, Jennifer
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 135 - 135
  • [29] Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
    Rahbar, Kambiz
    Schmidt, Matthias
    Heinzel, Alexander
    Eppard, Elisabeth
    Bode, Axel
    Yordanova, Anna
    Claesener, Michael
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (09) : 1334 - 1338
  • [30] Impact of pre-treatment hemoglobin (Hgb) on outcomes in metastatic castration resistant prostate cancer (mCRPC) with lutetium-177-PSMA-617 (Lu-177)
    Nelson, Ariel Ann
    Riemersma, Kristin
    Bylow, Kathryn A.
    Holt, Michael
    Kilari, Deepak
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345